Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
Pharming Group is a global biotechnology company that develops and commercializes innovative therapies for rare and ultra-rare diseases with significant unmet need. We focus on immunological and genetic conditions where our scientific and commercial expertise can help advance care over the long term. Patients are at the heart of everything we do. Their insights along with those of caregivers and the scientific community shape our strategy, guide our clinical study designs, and influence how we manage our approved therapies. Our teams combine deep scientific, medical, and operational expertise in rare disease drug development and commercialization. We leverage proven and efficient clinical development, supply chain, and commercial infrastructure to advance and expand our portfolio and pipeline and increase access for patient communities that currently lack adequate treatment options. We execute with discipline and urgency, pursuing strategic growth with focused resource allocation. By strengthening our commercial portfolio and advancing high-value pipeline programs, we aim to deliver sustainable long-term value for patients, healthcare providers, employees, partners, and shareholders. I. BUSINESS AND STRATEGIC DIRECTION 1. Our business Pharming is an integrated biotechnology company with proven capabilities across clinical development, manufacturing, regulatory affairs, and commercialization.
Read the full filing description · filed 2 Apr 2026
At a glance
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- CEO
- Fabrice Chouraqui PharmD MBA
Source: SEC filings. Information and analytics, not investment advice.